Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast

Forecasting

Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

RNC Pharma Database Update: Pharmaceutical Drug Production in Russia (May 2018)

Friday, June 29, 2018

Between January and May 2018, Russia produced 132.2 bln RUB worth of pharmaceutical drugs (dispatch prices, VAT included), which is in monetary terms 2.3% lower than that of the same period of 2017, despite the relatively high May performance. In physical terms, Russia produced only 1.63 bln units over the period, which is 12% lower than that of the same period of 2017.

The decreasing volumes are due to over-the-counter drugs (-13%.) The dynamics of the production of Rx drugs are -11%. When calculated in minimum dosage units (MDU), the dynamics of the over-the-counter drug production are -9%, while the dynamics of the production of Rx drugs are even positive, with +8.5%. In monetary terms, the dynamics of the production of over-the-counter drugs are -14% and +2% for the production of Rx drugs (January — May 2018.).

The following EphMRA groups still have the worst dynamics: antivirals for systemic use (-31%), painkillers (-22%), and cough and cold medicines (-18%). However, there are also positive dynamics. In particular, the dynamics of the production of antihistamine drugs are +32% (due to Vertex, increase in production +92%), and the dynamics of the production of medicines for liver and bile duct diseases are +18% (Avexima has increased its production by nearly 6 times.)

As for Rx drugs, the dynamics of the production of solutions for intravenous admission in physical terms are -43% and -24% for the production of anti-inflammatory and anti-rheumatic drugs. The dynamics of the production of beta-adrenoblockers are +64% (Severnaya Zvezda has increased its production by 3.4 times) and +21% for the production of diabetes medicines (Sanofi has doubled its production.).

Read more about pharmaceutical drug production in Russia (April results) here: http://rncph.com/news/31_05_2018

Dynamics of pharmaceutical drug production in Russia, including production of pharmaceuticals of foreign companies on owned or contract plants, in physical (units) and monetary terms (RUB, VAT included) (January 2017 – May 2018)

Share: